4Venugppalan P, Sapre A, Venkatesan N, et al. Pelleted bioadhesive polymeric nanoparticles for buceal delivery of insulin: preparation and characterization. Pharmazie 2001 ;56(3) :217 - 219.
5IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes:recommendations for standard, comprehensive, and minimal care. Diabet Med 2006 ;23 : 579 - 593.
6Nathan DM. Buse JB. Davidson MB, et al. American Diabetes Association:European Association for the Study of Diabetes. Managemeat of hyper glycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European AssociatiOn for the Study of Diabetes. Diabetologia 2006;49:1711 - 1721.
7Ratner R, Goldberg R, Haffner S, et al. Diabetes Prevention Program Research Group. Impact of intensive ligestyle and meformin therapy O15 cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 2005;28:888-894.
8Stumvoll M , Nurjhan N, Perriello G, et al. Metabolic effects of metforminin non - insulin - dependent diabetes meUitus. N Engl J Med 1995 ;333 : 550 - 554.
1[1]Janson J, Richanl AS, David H, et al. Humanislet anyloid polypeptide(hIAPP) cytotoxicty is caused by membrane damage[J]. Diabetes, 1998, 47(Suppl Ⅰ) :A250
2[2]Janson J Richard A, S, peter B, et al. The mechamism of islet anyloidpolypeptide toxicity ismembramedisruptionbyintermediatesized toxie amyloid particles[J] .Diabetes, 1999, 48:491 - 498
5Pratley RE,Foley JE ,Dunning BE. Rapid actingin sulinotropic agents :restoration of early insulin secretion as a physiologic approach to improve glucose control. Curr Pharm Des, 2001 ; 7 (14) :1375-1397.
6Malaisse WJ, Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: The meglitinide family. Horm Metab Res, 1995,27:263-266.
7Yamato T, Ishikawa K, Ojima K, et al. Effects of KAD-1229 on postgrandial hyperglycemia after oral meal load in STZ-induced diabetic rats. Jpn J Pharmacol, 2001 - 85 (suppll) : AbstP-602.
8Misawa K, Ishikawa K, Oiima K, et al. Effects of KAD-1229,a nonsulfonylurea hypoglycemic agent,on plasma glucose and insulin in streptozotocin-induced diabetic dogs. Pharmacology.2001,62 (2) :65.
9Yamada N, Shigeta Y, Kaneko T,et al. Hypoglycemic effects and safety of a novel rapid-acting insulinotropic agent, KAD-1229, for NIDDM. Diabetes, 1996 ; 45 (Suppl 2) : Abst265.
10Ohnota H,Koizumi T,Tsutsumi N,et al. Novel rapld-and short-acting hypoglycemic agent, a calcium (2S)-2-benzyl-3- (cis-hexahydro-2-isoindolinylcarbonyl ) propionate (KAD-1229) that acts on the sulfonylurea receptor:Comparison of effects between KAD-1229 and gliclazide. J Pharmacol Exp Ther, 1994,269 : 489 - 495.
6Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95, 783 individuals followed for 12.4 years[J]. Diabetes Care, 1999, 22(2): 223-240.
7Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice[J]. Diabetologia, 2003, 46(6): 733-749.
